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Patients with acute asthma attending the emergency room were included in a double-blind, double-dummy and 
parallel group study to investigate whether a dry powder inhaler (Turbuhalers) can be used in acute asthma. If so, 
the aim was to establish the potency relationship between a/3,-agonist (salbutamol) administered by the dry powder 
inhaler and the pressurized metered-dose inhaler (pMD1). 
Eighty-six patients with a mean age of 38 years and forced expiratory volume in 1 s (FEV,) of 37% of predicted 
normal value were randomized at Siriraj Hospital in Bangkok to either Turbuhaler (50,ug dose - i) or pMD1 
(100 pg dose - ‘) with spacer (VolumaticE). Doses of 100 + 300+ 300+ 300 pg salbutamol were given at 0, 15, 30 and 
45 min via Turbuhaler and repeated at 90, 105, 120 and 135 min (total dose 2OOOpg). The same inhalation schedule 
with identical number of doses was used for the pMD1 with spacer but in double doses (total 4000 pg), assuming a 
dose-potency ratio of salbutamol administered via Turbuhaler compared with the pMD1 of 2: 1. At 85 min after the 
first dose, 60 mg prednisolone was given orally. FEV, was measured 10 min after each dosing. Peak inspiratory flow 
(PIF) through Turbuhaler was measured on each dosing occasion. Plasma (P)-salbutamol, serum @)-potassium 
concentrations, pulse rate, blood pressure and adverse events were recorded. 
No statistically significant differences were observed in the increase in FEV, between the groups: 55 min (165 min) 
after the first dose, the increase was 0.47 1 and 47% (0.64 1 and 63%) in the Turbuhaler group, and 0.46 1 and 42% 
(0.68 1 and 65%) in the pMD1 group. Mean PIF though Turbuhaler was 49 1 min ~ ’ (range 26-68) at first inhalation 
and increased to 60 1 min - ’ (range 38-86). There was no correlation between the initial PIF through Turbuhaler 
and the initial FEV, response. P-salbutamol and S-potassium values correlated well. A larger decrease in 
S-potassium was noticed after 75 min in the pMD1 group (0.38 mmol l- ‘) compared with the Turbuhaler group 
(0.23 mmol l- ‘) (P=O.O2). 
In conclusion, the use of a dry powder inhaler, Turbuhaler, was investigated in the emergency room treatment of 
acute asthma, and was as effective as a pMD1 with spacer. Half the dose of salbutamol administered via Turbuhaler 
was as effective as the full dose given via a pMDI with spacer. 
RESPIR. MED. (1998) 92, 167-172 
Introduction 
Inhaled &agonists given by pressurized metered-dose 
inhalers (pMD1) or nebulizers are well established in the 
treatment of acute asthma and other obstructive airway 
diseases (1). They are associated with a rapid onset of 
action, good efficacy at low doses and few adverse events. 
Salbutamol is a relatively selective &-agonist which has 
been on the market for several years. Treatment with 
Received 11 December 1996 and accepted in revised form 4 
March 1997. 
Correspondence should be addressed to: E. StBhl, Astra Draco AB, 
P.O. Box 34, S-221 00 Lund, Sweden. 
nebulized short-acting &agonists is still the most used 
treatment in patients with acute asthma (2). Inhalation via 
a pMD1 with spacer has also been shown to be effective and 
is a well-established method of delivering the drug directly 
to the airways in patients with acute asthma (3-5). The use 
of pMDIs, however, has some drawbacks, as they require 
propellants and lubricants to operate accurately, and these 
additives may cause or increase bronchospasm in some 
asthmatic individuals (68). 
Turbuhalera is an inspiratory-flow-driven, multi-dose, 
dry powder inhaler developed by Astra Draco AB, Sweden, 
for administration of drugs to the lungs (9). Recently, 
efficacy studies in patients with stable asthma have indi- 
cated that half the dose of salbutamol via pMD1 is required 
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via Turbuhaler to achieve the same bronchodilating 
response (10,ll). This 2:l relationship in lung efficacy has 
also been shown for terbutaline (12) and budesonide (13). 
Lung deposition data support this dose-potency relation- 
ship (12). This is in line with the findings recently published 
that asthmatic patients with acute asthma performed 
significantly better when the same dose of terbutaline was 
administered via Turbuhaler than via pMD1 and spacer 
(Nebuhaler@) (14). 
The objective of this study was to investigate whether the 
dry powder inhaler can be used in acute asthma and, if so, 
to establish the potency relationship between salbutamol 
Turbuhaler and salbutamol pMD1 and spacer (Volumatic). 
Methods 
PATIENTS 
A total of 86 Thai asthmatic patients, attending the emer- 
gency room (ER) at Siriraj Hospital in Bangkok, Thailand, 
were enrolled into the study between September 1994 and 
July 1995. The inclusion criteria were: (i) age between 16 
and 50 years; (ii) FEV, between 20 and 50% of predicted 
normal value; and (iii) a pulse rate of more than 100 
beats min - ’ adopting criteria used in earlier studies of 
acute asthma (15-17). The study protocol was approved by 
the Ethics Committee at Siriraj Hospital. Each patient gave 
signed informed consent before the start of the study. The 
study was conducted in accordance with the principles 
stated in the Declaration of Helsinki and according to FDA 
Regulations and Guidelines of Good Clinical Practice. 
DESIGN 
The study was of a randomized, double-blind, double- 
dummy parallel group design. Demographic data and 
asthma therapy taken within 24 h before arrival at the ER, 
as well as current therapy, were recorded. Oxygen therapy 
was given to all patients during the study via a nasal prong. 
Inhalation technique was standardized for the two inhalers 
according to the manufacturers’ recommendation. The 
inhalers were primed prior to the start of the procedures, 
and the spacer was primed with a placebo in order to reduce 
static charge. 
The patients were randomized to either salbutamol 
Turbuhaler (50 pug dose ~ ‘) or salbuterol pMD1 
(lOOpug dose- ‘). Doses of 100+300+300+300~g salbuta- 
mol were given at 0, 15, 30 and 45 min via Turbuhaler and 
repeated at 90, 105, 120 and 135 min (total dose 2OOOpg). 
The same inhalation schedule with an identical number of 
doses was used for the pMD1 with spacer but in double 
doses (total 4OOOpg), assuming a dose-potency ratio of 
salbutamol administered via Turbuhaler compared with the 
pMD1 of 2:l. At 85 min after the first dose, 60 mg pred- 
nisolone was given orally [Fig. l(a)]. FEV, was measured 
10 min after each dose of albuterol, at 75 min and at the 
completion of the study (165 min) [Fig. l(b)]. Blood samples 
were taken before and 75 and 165 min after the study start. 
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FIG. 1. (a) Randomization schedule. (b) Inhalation 
schedule and time of measurements of forced expiratory 
volume in 1 s (FEV,). 
MEASUREMENTS 
FEV, was obtained in a sitting position using the 
Vitalographa Alpha spirometer (Vitalograph Ltd, U.K.). 
Before the spirometry test was performed (best of three 
measurements, if possible), pulse rate (beats min ~ ‘) and 
blood pressure (mmHg) were measured, possible adverse 
events were recorded, and blood samples were taken for 
analysis of serum (S)-potassium and plasma (P)- 
salbutamol. At the first inhalation on each dosing occasion 
via Turbuhaler and via pMD1 with spacer, peak inspiratory 
flow (PIF) through the inhalers was measured by connect- 
ing Turbuhaler and the pMD1 with spacer to Vitalograph 
MD1 Modified Compact (Vitalograph Ltd, U.K.). A 
subjective question on clinical symptoms (‘How is your 
asthma now?‘) using a visual analogue scale (VAS: O-100 
where O=no symptoms and lOO=severe symptoms) was 
included. S-potassium was analysed at the Bioanalytical 
Chemistry Department, Astra Draco AB, using COMBAS, 
MIRA PLUS, Serial No. 30-5929, Roche Diagnostics, 
Basel, Switzerland. The concentration of P-salbutamol was 
determined by a gas chromatography-mass spectrometry 
method at the Bioanalytical Chemistry Department (IS). 
STATISTICAL ANALYSIS 
The primary efficacy variable was the 55-min measurement 
of FEV,, which was compared between the groups, using 
the baseline measurement as covariate in an ANOVA. The 
model is multiplicative, so the logarithm of both variables 
was used in the analysis. For descriptive purposes, the ratio 
of the 55-min measurement over the entry measurement 
(baseline) was used as effect variable. The adjusted percent- 
age increase from baseline was obtained by exponentiating 
back to the original scale. 
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TABLE 1. Baseline characteristics of patients 
Characteristics 
Turbuhaler ” 
(n=43) 
pMDI and spacer 
(n=43) 
Age (years) 40 (1649) 37 (1649) 
Sex (M/F) 14129 18/25 
Current smokers (no.) 3 5 
Duration of asthma (years) 17 (l-42) 19 (l-40) 
FEV, (1) 0.88 (0.3771.35) 0.92 (0.42-1.53) 
% predicted 37.5 (2049) 36.3 (2049) 
Pulse rate (beats min ~ ‘) 108 (101-122) 108 (102-136) 
BP (mmHg) systolic/diastolic 126181 129/84 
Clinical symptoms (visual analogue scale, l-100) 69 (25-96) 70 (31-96) 
PIF through Turbuhaler (1 min ~ ‘) 49 (26-68) 47 (21-77) 
PIF through pMD1 and spacer (1 min - ‘) 18 (7733) 16 (6-32) 
Values of continuous variables are expressed as mean (range). 
PIF, peak inspiratory flow; pMD1, pressurized metered-dose inhaler. 
Systemic effect variables (pulse rate, blood pressure and 
S-potassium) were analysed in the same way, except that 
additive models were used. 
In addition, a few other time points were analysed in the 
same way (lo-min and 165-min value of FEV,, 75-min and 
165-min value of S-potassium). 
With 40 evaluable patients in each group, there was an 
80% chance of detecting a difference in the increase in FEV, 
that was at least 62% of the standard deviation. With a 
standard deviation of 0.4 1, a difference of 0.25 1 would be 
detectable. This assumes a two-sided significance level of 
5%. 
Results 
STUDY POPULATION 
In total, 86 patients (54 women) were enrolled and rand- 
omized, and all were evaluable. Their mean age was 38 
years (range 1649). Table 1 shows the baseline character- 
istics in the two groups. Of the 86 patients, 30 used inhaled 
steroids, 49 patients used oral j&-agonists and 48 patients 
used xanthines as concomitant medication. The two 
treatment groups were comparable with regard to the 
concomitant medication. 
One patient, randomized to the pMDI group, discontin- 
ued due to worsening of airway symptoms after taking the 
dose given at 45 min. FEV, measurement at 55 min and 
S-potassium at 75 min were taken and these values are 
included in the analysis. 
SPIROMETRY 
Both groups markedly improved in lung function over time. 
The mean increase of FEV, from baseline to 55 min after 
first dose was 0.47 1 (47%) in the Turbuhaler group and 
0.46 1 (42%) in the pMD1 group. Figure 2 shows the FEV, 
values at each time point. There was no statistically signifi- 
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FIG. 2. Absolute mean values of forced expiratory 
volume in 1 s (FEV,) with time. -, Turbuhaler; ~ ~ -, 
pressurized metered-dose inhaler. Arrows indicate dosing 
time. 
cant difference between the groups at any time point [95% 
confidence interval (CL): - 7, - 15”/,]. Ten minutes after 
the first dose, the mean increase was 23% in the Turbuhaler 
group and 19% in the pMD1 group. At the end of the study 
(165 min after the first dose), the increase was 63% in the 
Turbuhaler group and 65% in the pMD1 group, ranging 
from 19 to 158%. An analysis also showed that the increase 
in FEV, was not significantly dependent on the duration of 
asthma. 
The mean values of PIF through Turbuhaler were 
49 1 min ~ ’ (range 26668) at first inhalation and increased 
to 601min~’ (range 38-86) at the last inhalation. The 
correlation was not statistically significant between the 
initial PIF through Turbuhaler and the initial FEV, 
response (Fig. 3). The initial mean values of PIF through 
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FIG. 3. Correlation between initial peak inspiratory flow 
(PIF) through Turbuhalera and initial forced expiratory 
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FIG. 4. Mean values of clinical symptoms (O=no symp- 
toms, 100 = severe symptoms). --, Turbuhaler; - - -, 
pressurized metered-dose inhaler. 
pMD1 with spacer were 16 1 mini i (range 6-32) and 
21 1 min- ’ (range 6-30) at the last inhalation. 
SYMPTOMS 
Clinical symptom scores on the VAS decreased in both 
treatment groups. The baseline variables were, on average, 
70 in both groups; at 165 min, the values were 8 in the 
Turbuhaler group and 6 in the pMD1 group. Figure 4 
shows the effect with time, which was statistically significant 
in both groups without any significant difference between 
the two groups. A correlation with FEV, was observed with 
a slope of - 0.60 with 95% C.I. of - 0.75 and - 0.46. 
SYSTEMIC EFFECTS 
There was a decrease in pulse rate and blood pressure 
during the study period with no statistically significant 
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FIG. 5. Mean values of the decrease in pulse rate. -, 
Turbuhaler. ~ - -, pressurized metered-dose inhaler. 
Arrows indicate dosing time. 
difference between the groups. Figure 5 shows the decrease 
in pulse rate with time. The mean baseline value of 
S-potassium was 4.01 mmol l- i in the Turbuhaler group 
and 4.11 mmol 1 - ’ in the pMD1 group. After 75 min, S- 
potassium in the pMD1 group had decreased by 
0.38 mmol 1~ ’ compared with 0.23 mmol l- ’ in the 
Turbuhaler group. The difference, 0.16 mmol l- ‘, has 95% 
C.I. of 0.02 and 0.29 (P=O.O2). At the end of the 
study, 165 min after the first dose, the total decrease 
was 0.48 mmol 1 - ’ with pMD1 with spacer and 
0.40 mmol l- ’ with Turbuhaler. The difference was not 
statistically significant. 
A number of patients entered with significant amounts of 
measurable salbutamol in plasma. Looking at the median 
increase, the P-salbutamol increased from 8.1 pmol l- ’ 
(baseline) to 19.5 pmol 1 - ’ (75 min) and to 32.7 pmol 1 - ’ 
(165 min) in the Turbuhaler group. The corresponding 
values were 11.0, 28.4 and 42.0 pmol l- ’ in the pMD1 
group. 
The level of S-potassium correlated well with the plasma 
concentration of salbutamol (a slope of - 0.020, C.I. 
- 0.022 and - 0.017) so that higher P-salbutamol corre- 
sponded to lower S-potassium [Fig. 6(a)]. Pulse rate was 
also shown to correlate inversely with P-salbutamol with 
the slope of - 0.47 (C.I. - 0.61, - 0.35). This shows that 
the increased concentrations of salbutamol did not result in 
a higher pulse rate [Fig. 6(b)]. 
Two adverse events (both headache) were reported by 
one patient in each treatment group. No serious adverse 
events were reported. 
Discussion 
The present study showed that a dry powder inhaler can be 
used in the treatment of patients with acute asthma, 
together with oxygen and high doses of systemic steroids, as 
suggested in recent guidelines (19). In addition, it was seen 
that salbutamol inhaled via Turbuhaler was as effective as 
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(a) S-potassium, and (b) pulse rate. 
salbutamol via pMD1 with spacer, but at half the dose. In 
the present study, a total of 4 mg was given by multiple 
actuations via pMD1 according to the guidelines on man- 
agement of acute asthma (19). This corresponds to half the 
dose given via Turbuhaler (2 mg). The differences in effect 
between Turbuhaler and pMD1 were very small and were 
not statistically significant; thus both administrations can 
be considered to be equally effective in improving lung 
function. These results are in accordance with another 
study performed in acute asthma comparing terbutaline 
inhaled via Turbuhaler and via pMD1 and spacer (14). In 
that study, the nominal doses were the same via both 
devices. 
The present results also support recently published 
reports in stable asthma showing that the same broncho- 
dilating response can be achieved with half the dose of 
salbutamol given by Turbuhaler compared with pMD1 
(10,ll). Another study has shown that the lung deposition 
after Turbuhaler inhalation is twice the lung deposition 
after a pMD1 inhalation. This relationship was also 
reflected in the efficacy measured as FEV, (12). 
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In the present study, a plateau seemed to have been 
reached with regard to bronchodilatation after inhalation 
of half the total salbutamol dose. However, after inhaling 
the remaining doses, a further increase occurred. This 
increase may be due to the improved delivery of the 
subsequent doses because of widening of the airways. 
Another explanation may, of course, be that the increase 
was due to the dose of oral prednisolone given after half the 
total salbutamol dose; 35 min after oral prednisolone, 
the further increase occurred. Similar findings have been 
published showing that prednisolone given as a single 
dose intravenously restored responsiveness to inhaled 
&-agonists (20). However, these findings were obtained 1 h 
after the prednisolone was given. 
The subjective judgement of the patients condition 
measured by a VAS appeared to be similar in the two 
groups. A correlation with the objective measures of FEV, 
was observed. However, the clinical symptoms were almost 
at zero at completion of the study, whereas the FEV, was, 
on average, 64% of predicted in both groups. Once again, 
this discrepancy confirms the difficulty patients have in 
estimating their actual degree of airway obstruction, and 
stresses that objective measurements are essential for evalu- 
ating therapeutic success in the treatment of acute asthma. 
Mean PIF through Turbuhaler at the study inclusion 
was 501min-’ and slightly lower than in another study in 
patients with acute asthma (21). PIF through Turbuhaler 
increased by time up to 60 1 min- ’ which could be a 
learning effect, but could also be an indication of a thera- 
peutic response. The values of PIF through Turbuhaler in 
patients during the stable phase of the asthma disease have 
been shown to be between 50 and 60 1 min - ‘, which is 
comparable with the values in the present study (22)). It has 
been of some concern whether patients with deteriorating 
asthma and low FEV, produce sufficient inspiratory effort 
in order to obtain an appropriate dose from Turbuhaler. In 
this study, no statistically significant increase in response 
was seen with higher PIF. Many patients clearly has a large 
response even when inhaling through Turbuhaler with a 
PIF of less than 50 1 min ~ ‘, This means that patients with 
decrease in lung function due to acute asthma are able to 
benefit from drugs inhaled via Turbuhaler. 
Pulse rate, systolic and diastolic blood pressure and 
S-potassium were assessed as markers of systemic drug 
effects. On pulse rate and blood pressure, small systemic 
effects were seen and no treatment difference was detected. 
Pulse rate decreased by lo-12 beats min ~ ’ after the first 
two doses and remained at that level. The high doses of 
/$-agonists given did not further affect the pulse rate at the 
end of the study. This is in accordance with a study 
performed by Jansen and Herala (23). In that study, 
significant increase in lung function was noticed without 
significant changes in pulse rate, respiratory rate or tremor. 
This can be explained by the fact that patients with acute 
asthma have a high sympathetic drive, which decreases after 
treatment and thereby masks any systemic side-eRects the 
treatment may have. 
There was a slightly greater effect on S-potassium when 
salbutamol was given by pMD1 with spacer as compared 
with the administration by Turbuhaler. However, the 
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P-salbutamol values correlated well with S-potassium in 
contrast to a study where plasma concentration in relation 
to the &agonist intake was studied (24). 
In conclusion, the use of a dry powder inhaler such as 
Turbuhaler was investigated in the emergency room treat- 
ment of acute asthma, and was as effective as a pMD1 with 
spacer. Half the dose of salbutamol via Turbuhaler was as 
effective as the full dose given via pMD1 with spacer. 
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